Status:

NOT_YET_RECRUITING

Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR

Lead Sponsor:

Universitair Ziekenhuis Brussel

Conditions:

Preeclampsia (PE) Risk

Oocyte Donation

Eligibility:

FEMALE

Brief Summary

The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on ...

Eligibility Criteria

Inclusion

  • Every live birth delivery post oocyte donation (mother, child, donor).

Exclusion

  • Unknown HLA-C/KIR typing of acceptor, donor or offspring (resumlts of all 3 parties must be present to participate.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2029

Estimated Enrollment :

2325 Patients enrolled

Trial Details

Trial ID

NCT07178652

Start Date

September 1 2025

End Date

August 1 2029

Last Update

September 17 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR | DecenTrialz